Navigation Links
Ferring Pharmaceuticals' FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
Date:8/16/2010

PARSIPPANY, N.J., Aug. 16 /PRNewswire/ -- Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), is in the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge / Dash for Dad, the premier prostate cancer race series in the United States, led by ZERO – The Project to End Prostate Cancer.  FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer.

"ZERO's Dash for Dad exemplifies the determination needed to beat prostate cancer," said William Garbarini, Vice President, US Marketing, Ferring Pharmaceuticals Inc. "It is inspiring to see athletes, doctors and friends—but especially survivors and family members—race with such commitment to stop prostate cancer in its tracks. We are proud to support their efforts."  

This year, ZERO expects more than 7,000 participants across 14 cities in the Great Prostate Cancer Challenge / Dash for Dad.  Baltimore, Nashville, and Indianapolis are just a few of the cities where running races and walks will be held.  The widespread exposure generated by the events will go a long way toward advancing the organization's mission—zero tolerance for prostate cancer.

The first Dash for Dad race took place in 2008 in an effort to promote prostate cancer awareness, early detection and research. To date, the national series has raised more than one million dollars.  ZERO – The Project to End Prostate Cancer, dedicates the proceeds from each event to free prostate cancer screenings in the host community.

"We are thrilled Ferring has joined our race to end prostate cancer," said ZERO's CEO Skip Lockwood.  "Their product FIRMAGON is an important treatment option for advanced prostate cancer patients, and reflects their determination to help provide effective treatment for patients suffering with this disease. Teaming up will strengthen our ability to cross the finish line, and reach our goal."

Prostate cancer is diagnosed every two minutes and 15 seconds, and takes about one life every 18 minutes.  It is the most common non-skin cancer, and the second leading cause of cancer death in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of this disease.

To get information on a Great Prostate Cancer Challenge / Dash for Dad event in your area, visit: http://www.GreatProstateCancerChallenge.com/

About ZERO – The Project to End Prostate Cancer

Zero prostate cancer deaths. Zero prostate cancer cases and for those with prostate cancer, it means a zero PSA. The name stands for zero tolerance for prostate cancer.  ZERO - The Project to End Prostate Cancer is committed to not only reducing prostate cancer and alleviating pain from the disease but to end it. They see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life, with the support they need to minimize physical and emotional suffering and to cope effectively throughout their cancer journeys. They provide comprehensive treatment information to patients, education to those at risk and conduct free prostate cancer testing throughout the country. They increase research funds from the federal government to find new treatments and fund local grants to end the disease.

About FIRMAGON

FIRMAGON is a prescription medicine used in the treatment of advanced prostate cancer.

Important Safety Information

FIRMAGON should not be given to people who are allergic to any of the ingredients in FIRMAGON.  It should not be given to women who are pregnant or may become pregnant.  FIRMAGON can harm an unborn baby when given to a pregnant woman.

Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems, problems with balance of your body salts or electrolytes (such as, sodium, potassium, calcium, and magnesium), or have kidney or liver problems.

The common side effects of FIRMAGON  include: hot flashes, injection site pain, redness and swelling (especially with the first dose), weight gain, increase in some liver enzymes, tiredness, hypertension, back and joint pain, chills, urinary tract infection, and decreased sex drive and trouble with erectile function (impotence). Please see Full Prescribing Information at www.Firmagon.com.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a Swiss-headquartered, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, reproductive health and urology. Ferring Pharmaceuticals offers a line of urology, infertility, gynecology, and orthopaedic products in the U.S. market. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com http://www.ferringusa.com/.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
2. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
3. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
4. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
5. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
6. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
7. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG ... the PW Series Solvent Recycling Systems, specifically designed ... full integration with new and existing vapor degreasers, ... produces consistently-fresh solvent through continuous recycling and recovers ... --> --> Precision parts ...
(Date:2/8/2016)... 8, 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... fourth quarter and year-end 2015 results after the Nasdaq ... then host a live conference call and webcast to ... Thursday afternoon, February 11, 2016 at 4:30 p.m. Eastern ... --> http://www.neurocrine.com . --> Participants ...
Breaking Medicine Technology:
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 ... in honor of his birthday on February 10th. During this time, people can ... known by over 250,000 people from over 40 different countries as an “ordinary man ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to ... the U.S. require dental technicians to be certified or obtain continuing education. To ... created the “What’s In Your Mouth?” campaign to inform dentists and patients about ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... in recognition of National Wear Red Day. National Wear Red Day is the ... stroke in women. Heart disease and stroke cause 1 in 3 deaths among women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood ... his medical and surgical expertise. Technically known as deoxycholic acid or previously as ... a non-surgical alternative for reduction of fat below the chin (aka the “double ...
Breaking Medicine News(10 mins):